30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: Anika Therapeutics

Orthobiologics $12.8MM, +39% (U.S. +26%)

  • ORTHOVISC remains primary growth driver
  • Claims #1 position in U.S. multi-injection segment
  • Ex-U.S. viscosupplementation sales +83% YTD
  • Strong MONOVISC, ORTHOVISC sales in Canada through new distributor
  • Growing global interest in Hyalofast cartilage regeneration product
  • Expanded and initiated back-up sites to accelerate enrollment in Phase III multinational study of Cingal in treatment of knee osteoarthritis; enrollment slated for completion 1Q14
  • Submitted CE Mark dossier for Hyalospine anti-adhesion product; expecting approval by end of 1Q14
  • MONOVISC U.S. status: FDA review of additional analysis complete, feedback expected in 4Q13